BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21173253)

  • 1. Resistance to discodermolide, a microtubule-stabilizing agent and senescence inducer, is 4E-BP1-dependent.
    Chao SK; Lin J; Brouwer-Visser J; Smith AB; Horwitz SB; McDaid HM
    Proc Natl Acad Sci U S A; 2011 Jan; 108(1):391-6. PubMed ID: 21173253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence.
    Klein LE; Freeze BS; Smith AB; Horwitz SB
    Cell Cycle; 2005 Mar; 4(3):501-7. PubMed ID: 15711127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence.
    Chao SK; Horwitz SB; McDaid HM
    Oncotarget; 2011; 2(1-2):89-98. PubMed ID: 21399233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation.
    Honore S; Kamath K; Braguer D; Wilson L; Briand C; Jordan MA
    Mol Cancer Ther; 2003 Dec; 2(12):1303-11. PubMed ID: 14707271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
    Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E
    Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total synthesis of a potent hybrid of the anticancer natural products dictyostatin and discodermolide.
    Paterson I; Naylor GJ; Wright AE
    Chem Commun (Camb); 2008 Oct; (38):4628-30. PubMed ID: 18815706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into the interaction of discodermolide and docetaxel with tubulin. Mapping the binding sites of microtubule-stabilizing agents by using an integrated NMR and computational approach.
    Canales A; Rodríguez-Salarichs J; Trigili C; Nieto L; Coderch C; Andreu JM; Paterson I; Jiménez-Barbero J; Díaz JF
    ACS Chem Biol; 2011 Aug; 6(8):789-99. PubMed ID: 21539341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Refinement of the Tubulin Ligand (+)-Discodermolide to Attenuate Chemotherapy-Mediated Senescence.
    Guo B; Rodriguez-Gabin A; Prota AE; Mühlethaler T; Zhang N; Ye K; Steinmetz MO; Horwitz SB; Smith AB; McDaid HM
    Mol Pharmacol; 2020 Aug; 98(2):156-167. PubMed ID: 32591477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct pose of discodermolide in taxol binding pocket drives a complementary mode of microtubule stabilization.
    Khrapunovich-Baine M; Menon V; Verdier-Pinard P; Smith AB; Angeletti RH; Fiser A; Horwitz SB; Xiao H
    Biochemistry; 2009 Dec; 48(49):11664-77. PubMed ID: 19863156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin.
    Madiraju C; Edler MC; Hamel E; Raccor BS; Balachandran R; Zhu G; Giuliano KA; Vogt A; Shin Y; Fournier JH; Fukui Y; Brückner AM; Curran DP; Day BW
    Biochemistry; 2005 Nov; 44(45):15053-63. PubMed ID: 16274252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of accelerated senescence by the microtubule-stabilizing agent peloruside A.
    Chan A; Gilfillan C; Templeton N; Paterson I; Northcote PT; Miller JH
    Invest New Drugs; 2017 Dec; 35(6):706-717. PubMed ID: 28733703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells.
    Honore S; Kamath K; Braguer D; Horwitz SB; Wilson L; Briand C; Jordan MA
    Cancer Res; 2004 Jul; 64(14):4957-64. PubMed ID: 15256469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of natural product microtubule stabilizers on microtubule assembly: single agent and combination studies with taxol, epothilone B, and discodermolide.
    Gertsch J; Meier S; Müller M; Altmann KH
    Chembiochem; 2009 Jan; 10(1):166-75. PubMed ID: 19058273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol.
    ter Haar E; Kowalski RJ; Hamel E; Lin CM; Longley RE; Gunasekera SP; Rosenkranz HS; Day BW
    Biochemistry; 1996 Jan; 35(1):243-50. PubMed ID: 8555181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A photoaffinity analogue of discodermolide specifically labels a peptide in beta-tubulin.
    Xia S; Kenesky CS; Rucker PV; Smith AB; Orr GA; Horwitz SB
    Biochemistry; 2006 Oct; 45(39):11762-75. PubMed ID: 17002277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of (+)-discodermolide-paclitaxel hybrids leading to enhanced biological activity.
    Smith AB; Sugasawa K; Atasoylu O; Yang CP; Horwitz SB
    J Med Chem; 2011 Sep; 54(18):6319-27. PubMed ID: 21870795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Dose-Response Relationship of (+)-Discodermolide-Taxol Hybrid Congeners.
    Nadaradjane C; Yang CH; Rodriguez-Gabin A; Ye K; Sugasawa K; Atasoylu O; Smith AB; Horwitz SB; McDaid HM
    J Nat Prod; 2018 Mar; 81(3):607-615. PubMed ID: 29522336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationship studies of discodermolide and its semisynthetic acetylated analogs on microtubule function and cytotoxicity.
    Isbrucker RA; Gunasekera SP; Longley RE
    Cancer Chemother Pharmacol; 2001 Jul; 48(1):29-36. PubMed ID: 11488521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wild-type class I beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation.
    Wiesen KM; Xia S; Yang CP; Horwitz SB
    Cancer Lett; 2007 Nov; 257(2):227-35. PubMed ID: 17869412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines.
    Martello LA; McDaid HM; Regl DL; Yang CP; Meng D; Pettus TR; Kaufman MD; Arimoto H; Danishefsky SJ; Smith AB; Horwitz SB
    Clin Cancer Res; 2000 May; 6(5):1978-87. PubMed ID: 10815923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.